Neurosense Therapeutics Ltd. (NRSN) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Neurosense Therapeutics Ltd. (NRSN:NASDAQ), powered by AI.

Current Price
$0.70
P/E Ratio
-1.6
Market Cap
18M
Sector
Healthcare
What is the Neurosense Therapeutics Ltd. stock price forecast?

Neurosense Therapeutics Ltd. is currently trading at $0.70. View real-time AI analysis on Alpha Lenz.

What is Neurosense Therapeutics Ltd. insider trading activity?

View the latest insider trading data for Neurosense Therapeutics Ltd. on Alpha Lenz.

What is Neurosense Therapeutics Ltd.'s P/E ratio?

Neurosense Therapeutics Ltd.'s P/E ratio is -1.6.

Neurosense Therapeutics Ltd.

NASDAQ · NRSN
$0.70+0.01(+1.75%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Neurosense Therapeutics Ltd.'s future dividend policy...
Alpha Chat Insight

Neurosense Therapeutics Ltd. trades at a P/E of -1.6 (undervalued) with modest ROE of -2175.0%.

Ask for details

Company Overview

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company dedicated to developing innovative treatments for neurodegenerative diseases. Focusing primarily on targeting conditions like Amyotrophic Lateral Sclerosis (ALS), Alzheimer's, and Parkinson's disease, Neurosense leverages cutting-edge research to formulate therapeutic solutions that can address unmet medical needs. The company's research and development are rooted in a deep understanding of disease mechanisms, aiming to offer novel drug compounds that can alter the course of debilitating neurodegenerative disorders. Neurosense Therapeutics collaborates with academic institutions and research organizations to validate its scientific approaches, positioning itself as a significant player in the biotechnology sector. By advancing its drug candidates through rigorous clinical trials, the company aims to provide new hope for patients affected by these challenging diseases. Neurosense Therapeutics contributes to the global healthcare landscape by striving to deliver breakthroughs that could potentially improve quality of life for millions of patients worldwide.

CEOMr. Alon Ben-Noon
SectorHealthcare
IndustryBiotechnology
Employees17

Company Statistics

FY 2025

Profile

$17.81MMarket Cap
$0.00Revenue
0.00Shares Out
17Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-1.60P/E
-11.42P/B
N/AEV/Sales
-1.62EV/EBITDA
-2.32P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-397.11%ROA
-2174.98%ROE
-395.68%ROIC

Financial Health

$166.00KCash & Cash Equivalents
$2.42MNet Debt
-165.90%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Neurosense Therapeutics Ltd. (ticker: NRSN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 17 employees. Market cap is $18M.

The current price is $0.699 with a P/E ratio of -1.6x and P/B of -11.42x.

ROE is -2174.98%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Neurosense Therapeutics Ltd. (NRSN) Stock Forecast 2026 $0.70 — Price, Financials & Analyst Targets | Alpha Lenz